恩德拉生命科学
NDRA

股本结构

单位：万股
公告日期 2025-10-28 2025-10-15 2025-11-14 2025-07-09 2025-08-14 2025-05-15
证券总股本 116.64 149.71 78.69 75.28 75.24 73.84
普通股本 116.64 149.71 78.69 75.28 75.24 73.84
优先股 0.0017 未披露 0.0017 未披露 0.0017 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2025-10-16 2025-10-15 2025-09-30 2025-07-08 2025-06-30 2025-05-15
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2025-10-28 116.64 0.0017 定期报告 2025-10-16
2025-10-15 149.71 未披露
更多>>
Common Stock offered 744,340 shares by the company
2025-10-15
2025-11-14 78.69 0.0017
更多>>
From June 30, 2025 to September 30,2025 Common stock issued for cash
2025-09-30
2025-07-09 75.28 未披露 定期报告 2025-07-08
2025-08-14 75.24 0.0017
更多>>
From March 31,2025 to June 30,2025 Common stock issued for cash
2025-06-30
2025-05-15 73.84 未披露 定期报告 2025-05-15
2025-05-15 56.22 0.0017
更多>>
From December 31, 2024 to March 31, 2025 Fair value of vested common stock
2025-03-31
2025-03-31 56.22 未披露 定期报告 2025-03-24
2025-03-31 53.69 0.0017
更多>>
From December 31, 2023 to December 31, 2024 Common stock issued for cash Common stock issued for warrant exercise Common stock issued for cashless warrant exercise Fair value of vested common stock Preferred stock conversion to common stock
2024-12-31
2024-11-19 53.69 未披露 定期报告 2024-11-19
2024-11-05 51.83 未披露
更多>>
a 1-for-35 reverse stock split of the issued shares of its common stock
2024-11-07
2024-09-16 1813.98 0.0017 定期报告 2024-09-06
2024-08-28 1728.07 未披露 定期报告 2024-08-28
2024-08-16 140.00 未披露
更多>>
a 1-for-50 reverse stock split of the issued shares of its common stock
2024-08-20
2024-08-16 7240.00 未披露 定期报告 2024-08-16
2024-08-14 7243.95 0.0017
更多>>
From March 31, 2024 to June 30, 2024 Common stock issued for cash Preferred stock conversion to common stock Common stock issued for warrant exercise Common stock issued for cashless warrant exercise
2024-06-30
2024-06-25 7027.33 0.0017 定期报告 2024-06-12
2024-06-05 1714.34 未披露
更多>>
Common stock offered 6,107,691 shares by the company
2024-06-05
2024-05-14 1103.57 未披露 定期报告 2024-05-14
2024-05-14 1091.44 0.0035
更多>>
From December 31, 2023 to March 31, 2024 Common stock issued for warrant exercise Preferred stock conversion to common stock Common stock issued for cash Fair value of vested common stock for services
2024-03-31
2024-03-28 1103.57 0.0035 定期报告 2024-03-24
2024-02-14 1103.57 未披露 定期报告 2024-02-13
2024-03-28 1039.02 0.01
更多>>
From December 31, 2022 to December 31, 2023 Common stock issued for cash, net of funding costs Common stock issued for warrant exercise
2023-12-31
2023-11-14 845.49 未披露 定期报告 2023-11-14
2023-11-14 841.18 0.01
更多>>
From June 30, 2023 to September 30, 2023 Common stock issued for cash, net of funding costs
2023-09-30
2023-08-14 748.16 0.01
更多>>
From March 31, 2023 to June 30, 2023 Common stock issued for cash, net of funding costs
2023-06-30
2023-05-24 748.16 0.01 定期报告 2023-05-12
2023-04-28 691.91 未披露
更多>>
Common stock offered 3,750,000 shares by the company
2023-05-02
2023-05-15 316.91 14.14 定期报告 2023-03-31
2023-04-28 316.91 未披露 定期报告 2023-03-28
2023-03-16 316.91 14.14
更多>>
From December 31, 2021 to December 31, 2022 Common stock issued for cash, net of funding costs
2022-12-31
2022-12-08 315.87 未披露
更多>>
On December 8, 2022, ENDRA Life Sciences Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (Eastern time) on December 9, 2022 (the “Reverse Stock Split”).
2022-12-09
2022-10-17 6317.45 6.35 定期报告 2022-10-10
2022-08-15 6317.45 14.14
更多>>
From March 31, 2022 to June 30, 2022 Common stock issued for cash, net of funding costs
2022-06-30
2022-05-02 6317.45 未披露 定期报告 2022-04-25
2022-05-12 4455.94 14.14
更多>>
From December 31, 2021 to March 31, 2022 Common stock issued for cash, net of funding costs
2022-03-31
2022-03-30 4408.92 未披露 定期报告 2022-03-28
2022-03-30 4255.45 14.14
更多>>
From December 31, 2020 to December 31, 2021 Series A Convertible Preferred Stock converted to common stock Common stock issued for cash, net of funding costs Common stock issued for warrant exercise Common stock issued for option exercise Common stock issued for services Common stock issued for RSU
2021-12-31
2021-11-15 4216.57 14.14
更多>>
From June 30, 2021 to September 30, 2021 Common stock issued for cash, net of funding costs Common stock issued for option exercise Common stock issued for RSU
2021-09-30
2021-08-12 4185.74 0.01
更多>>
From March 31, 2021 to June 30, 2021 Common stock issued for warrant exercise Common stock issued for option exercise Stock payable for services
2021-06-30
2021-05-17 4167.27 未披露 定期报告 2021-05-17
2021-04-29 4164.02 0.01 定期报告 2021-04-22
2021-05-17 4161.47 0.01
更多>>
From December 31, 2020 To March 31, 2021 Series A Convertible Preferred Stock converted to Common Stock Common Stock issued for cash, net of funding costs Common Stock issued for warrant exercise Common stock issued for option exercise
2021-03-31
2021-03-25 4159.97 0.01 定期报告 2021-03-24
2021-02-19 3758.61 未披露 定期报告 2021-02-18
2021-03-25 3404.97 0.02
更多>>
From December 31, 2019 to December 31, 2020 Series A Convertible Preferred Stock converted to common stock Series B Convertible Preferred Stock converted to common stock Common stock issued for cash Common stock issued for note conversions Common stock issued for warrant exercise Common stock issued for services Common stock issued for vested RSUs
2020-12-31
2020-12-18 3292.70 未披露
更多>>
1.Common stock offered by the company 7,143,000 shares of common stock. 2.The number of shares of common stock to be outstanding after this offering is based on 25,784,038 shares of common stock outstanding as of December 14, 2020.
2020-12-18
2020-12-15 2578.40 未披露 定期报告 2020-12-14
2020-11-16 2510.36 未披露 定期报告 2020-11-13
2020-11-16 2501.57 0.02
更多>>
From June 30, 2020 to September 30, 2020 Series A Convertible Preferred Stock converted to common stock Common stock issued for cash Common stock issued for warrant exercises Common stock issued for services Common stock issued for RSUs
2020-09-30
2020-09-25 2487.92 未披露 定期报告 2020-09-24
2020-08-14 2096.10 未披露 定期报告 2020-08-13
2020-08-03 1637.12 0.10 定期报告 2020-07-07
2020-08-14 1643.75 0.09
更多>>
From March 31, 2020 to June 30, 2020 Series A Convertible Preferred Stock converted to common stock Series B Convertible Preferred Stock converted to common stock Common stock issued for cash Common stock issued for warrant exercise Common stock issued for services
2020-06-30
2020-05-14 1450.48 未披露 定期报告 2020-05-14
2020-04-29 1375.40 0.24 定期报告 2020-04-22
2020-05-14 1355.30 0.26
更多>>
From December 31, 2019 to March 31, 2020 Series A Convertible Preferred Stock converted to common stock Series B Convertible Preferred Stock converted to common stock Common stock issued for note conversions Common stock issued for warrant exercise
2020-03-31
2020-03-26 1348.31 未披露 定期报告 2020-03-23
2020-03-26 842.14 0.67
更多>>
From December 31, 2018 to December 31, 2019 Series A Convertible Preferred Stock issued Series B Convertible Preferred Stock issued Common stock issued for note conversions
2019-12-31
2019-11-13 751.69 未披露
更多>>
From June 30, 2019 to September 30, 2019 Common stock issued for note conversion
2019-09-30
2019-03-11 742.26 未披露
更多>>
from December 31, 2016 to December 31, 2018 Common stock issued for cash Common stock issued for note conversion
2018-12-31
2018-12-28 742.26 未披露 定期报告 2018-12-28
2018-11-05 542.56 未披露 定期报告 2018-11-02
2018-11-05 394.78 未披露 定期报告 2018-09-30
2018-03-20 392.30 未披露
更多>>
from December 31, 2016 to December 31, 2017 IPO shares Overallotment for IPO Note conversion Common stock issued for services
2017-12-31
2017-08-07 390.70 未披露 定期报告 2017-06-30
2017-06-28 364.03 未披露
更多>>
1.The number of shares of our common stock to be outstanding after this offering is based on 1,960,267 shares of common stock outstanding as of March 17, 2017, which includes the conversion of the outstanding principal and accrued interest on our outstanding convertible promissory notes at March 17, 2017 into an aggregate of 1,236,894 shares of our common stock at a conversion price of $1.40 per share immediately prior to the completion of this offering, as elected by the holders of a majority of the outstanding principal amount of such convertible promissory notes
2017-06-28
2017-06-21 390.70 未披露 定期报告 2017-06-13
2017-06-21 72.33 未披露
更多>>
On May 8, 2017, the Company effected a one-for-3.5 reverse stock split (the “Reverse Split”) of the Company’s common stock, with no reduction in authorized capital stock. In the Reverse Split, every 3.5 outstanding shares of common stock became one share of common stock.
2017-03-31
2017-05-01 196.03 未披露 定期报告 2017-03-17
2017-03-27 253.18 未披露
更多>>
from December 31, 2015 to September 30, 2016 Common stock issued for exercise of warrants
2016-09-30
2016-11-21 252.83 未披露
更多>>
From December 31, 2014 to December 31, 2015 Common stock issued for cash Common stock issued for exercise of warrants Common stock issued for accrued salaries - related parties
2015-12-31
Common Stock offered 744,340 shares by the company
From June 30, 2025 to September 30,2025 Common stock issued for cash
From March 31,2025 to June 30,2025 Common stock issued for cash
From December 31, 2024 to March 31, 2025 Fair value of vested common stock
From December 31, 2023 to December 31, 2024 Common stock issued for cash Common stock issued for warrant exercise Common stock issued for cashless warrant exercise Fair value of vested common stock Preferred stock conversion to common stock
a 1-for-35 reverse stock split of the issued shares of its common stock
a 1-for-50 reverse stock split of the issued shares of its common stock
From March 31, 2024 to June 30, 2024 Common stock issued for cash Preferred stock conversion to common stock Common stock issued for warrant exercise Common stock issued for cashless warrant exercise
Common stock offered 6,107,691 shares by the company
From December 31, 2023 to March 31, 2024 Common stock issued for warrant exercise Preferred stock conversion to common stock Common stock issued for cash Fair value of vested common stock for services
From December 31, 2022 to December 31, 2023 Common stock issued for cash, net of funding costs Common stock issued for warrant exercise
From June 30, 2023 to September 30, 2023 Common stock issued for cash, net of funding costs
From March 31, 2023 to June 30, 2023 Common stock issued for cash, net of funding costs
Common stock offered 3,750,000 shares by the company
From December 31, 2021 to December 31, 2022 Common stock issued for cash, net of funding costs
On December 8, 2022, ENDRA Life Sciences Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (Eastern time) on December 9, 2022 (the “Reverse Stock Split”).
From March 31, 2022 to June 30, 2022 Common stock issued for cash, net of funding costs
From December 31, 2021 to March 31, 2022 Common stock issued for cash, net of funding costs
From December 31, 2020 to December 31, 2021 Series A Convertible Preferred Stock converted to common stock Common stock issued for cash, net of funding costs Common stock issued for warrant exercise Common stock issued for option exercise Common stock issued for services Common stock issued for RSU
From June 30, 2021 to September 30, 2021 Common stock issued for cash, net of funding costs Common stock issued for option exercise Common stock issued for RSU
From March 31, 2021 to June 30, 2021 Common stock issued for warrant exercise Common stock issued for option exercise Stock payable for services
From December 31, 2020 To March 31, 2021 Series A Convertible Preferred Stock converted to Common Stock Common Stock issued for cash, net of funding costs Common Stock issued for warrant exercise Common stock issued for option exercise
From December 31, 2019 to December 31, 2020 Series A Convertible Preferred Stock converted to common stock Series B Convertible Preferred Stock converted to common stock Common stock issued for cash Common stock issued for note conversions Common stock issued for warrant exercise Common stock issued for services Common stock issued for vested RSUs
1.Common stock offered by the company 7,143,000 shares of common stock. 2.The number of shares of common stock to be outstanding after this offering is based on 25,784,038 shares of common stock outstanding as of December 14, 2020.
From June 30, 2020 to September 30, 2020 Series A Convertible Preferred Stock converted to common stock Common stock issued for cash Common stock issued for warrant exercises Common stock issued for services Common stock issued for RSUs
From March 31, 2020 to June 30, 2020 Series A Convertible Preferred Stock converted to common stock Series B Convertible Preferred Stock converted to common stock Common stock issued for cash Common stock issued for warrant exercise Common stock issued for services
From December 31, 2019 to March 31, 2020 Series A Convertible Preferred Stock converted to common stock Series B Convertible Preferred Stock converted to common stock Common stock issued for note conversions Common stock issued for warrant exercise
From December 31, 2018 to December 31, 2019 Series A Convertible Preferred Stock issued Series B Convertible Preferred Stock issued Common stock issued for note conversions
From June 30, 2019 to September 30, 2019 Common stock issued for note conversion
from December 31, 2016 to December 31, 2018 Common stock issued for cash Common stock issued for note conversion
from December 31, 2016 to December 31, 2017 IPO shares Overallotment for IPO Note conversion Common stock issued for services
1.The number of shares of our common stock to be outstanding after this offering is based on 1,960,267 shares of common stock outstanding as of March 17, 2017, which includes the conversion of the outstanding principal and accrued interest on our outstanding convertible promissory notes at March 17, 2017 into an aggregate of 1,236,894 shares of our common stock at a conversion price of $1.40 per share immediately prior to the completion of this offering, as elected by the holders of a majority of the outstanding principal amount of such convertible promissory notes
On May 8, 2017, the Company effected a one-for-3.5 reverse stock split (the “Reverse Split”) of the Company’s common stock, with no reduction in authorized capital stock. In the Reverse Split, every 3.5 outstanding shares of common stock became one share of common stock.
from December 31, 2015 to September 30, 2016 Common stock issued for exercise of warrants
From December 31, 2014 to December 31, 2015 Common stock issued for cash Common stock issued for exercise of warrants Common stock issued for accrued salaries - related parties
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。